Investigating the neuroprotective effect of AAV-mediated β-synuclein overexpression in a transgenic model of synucleinopathy

[1]  E. Morignat,et al.  ‘Prion‐like’ propagation of the synucleinopathy of M83 transgenic mice depends on the mouse genotype and type of inoculum , 2017, Journal of neurochemistry.

[2]  S. Khare,et al.  A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues , 2017, The Journal of Biological Chemistry.

[3]  D. Dickson,et al.  Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain , 2017, Acta neuropathologica communications.

[4]  Natalie Landeck,et al.  Toxic effects of human and rodent variants of alpha‐synuclein in vivo , 2017, The European journal of neuroscience.

[5]  Jacob I. Ayers,et al.  Robust Central Nervous System Pathology in Transgenic Mice following Peripheral Injection of α-Synuclein Fibrils , 2016, Journal of Virology.

[6]  Laetitia van Wittenberghe,et al.  Efficacy and biodistribution analysis of intracerebroventricular administration of an optimized scAAV9-SMN1 vector in a mouse model of spinal muscular atrophy , 2016, Molecular therapy. Methods & clinical development.

[7]  Alexander K. Buell,et al.  Mutations associated with familial Parkinson’s disease alter the initiation and amplification steps of α-synuclein aggregation , 2016, Proceedings of the National Academy of Sciences.

[8]  J. Baum,et al.  Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein , 2015, Scientific Reports.

[9]  B. Hutter-Paier,et al.  Influence of Lentiviral β-Synuclein Overexpression in the Hippocampus of a Transgenic Mouse Model of Alzheimer's Disease on Amyloid Precursor Protein Metabolism and Pathology , 2015, Neurodegenerative Diseases.

[10]  E. Morignat,et al.  Detection of Disease-associated α-synuclein by Enhanced ELISA in the Brain of Transgenic Mice Overexpressing Human A53T Mutated α-synuclein. , 2015, Journal of visualized experiments : JoVE.

[11]  Stacy D. Grunke,et al.  Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. , 2014, Journal of Visualized Experiments.

[12]  O. Isacson,et al.  Widespread neuron-specific transgene expression in brain and spinal cord following synapsin promoter-driven AAV9 neonatal intracerebroventricular injection , 2014, Neuroscience Letters.

[13]  Jacob I. Ayers,et al.  Intramuscular injection of α-synuclein induces CNS α-synuclein pathology and a rapid-onset motor phenotype in transgenic mice , 2014, Proceedings of the National Academy of Sciences.

[14]  E. Morignat,et al.  Alpha-synuclein spreading in M83 mice brain revealed by detection of pathological α-synuclein by enhanced ELISA , 2014, Acta neuropathologica communications.

[15]  C. Meshul,et al.  Presynaptic Alpha-Synuclein Aggregation in a Mouse Model of Parkinson's Disease , 2014, The Journal of Neuroscience.

[16]  Jasper Akerboom,et al.  β‐synuclein aggregates and induces neurodegeneration in dopaminergic neurons , 2013, Annals of neurology.

[17]  E. Morignat,et al.  Prion-like acceleration of a synucleinopathy in a transgenic mouse model , 2012, Neurobiology of Aging.

[18]  E. Waxman,et al.  E46K Human α-Synuclein Transgenic Mice Develop Lewy-like and Tau Pathology Associated with Age-dependent, Detrimental Motor Impairment* , 2011, The Journal of Biological Chemistry.

[19]  M. Ehlers,et al.  Optimizing promoters for recombinant adeno-associated virus-mediated gene expression in the peripheral and central nervous system using self-complementary vectors. , 2011, Human gene therapy.

[20]  W. Seol,et al.  Direct Interaction of α-Synuclein and AKT Regulates IGF-1 Signaling: Implication of Parkinson Disease , 2011, Neurosignals.

[21]  S. Inoue,et al.  A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brain , 2010, Nature communications.

[22]  W. Schulz-Schaeffer.  The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[23]  J. Wolfe,et al.  A Single Injection of an Adeno-Associated Virus Vector into Nuclei with Divergent Connections Results in Widespread Vector Distribution in the Brain and Global Correction of a Neurogenetic Disease , 2007, The Journal of Neuroscience.

[24]  John Q. Trojanowski,et al.  -synuclein modulates -synuclein neurotoxicity by reducing -synuclein protein expression , 2006 .

[25]  E. Masliah,et al.  An antiaggregation gene therapy strategy for Lewy body disease utilizing β-synuclein lentivirus in a transgenic model , 2004, Gene Therapy.

[26]  J. Trojanowski,et al.  β-Synuclein gene alterations in dementia with Lewy bodies , 2004, Neurology.

[27]  M. R. Delgado Alvira,et al.  Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.

[28]  E. Masliah,et al.  β-Synuclein Regulates Akt Activity in Neuronal Cells , 2004, Journal of Biological Chemistry.

[29]  Lili Wang,et al.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[30]  J. Trojanowski,et al.  Neuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein , 2002, Neuron.

[31]  J. Uney,et al.  Adenoviral-mediated, high-level, cell-specific transgene expression: a SYN1-WPRE cassette mediates increased transgene expression with no loss of neuron specificity. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[32]  Makoto Hashimoto,et al.  β-Synuclein Inhibits α-Synuclein Aggregation A Possible Role as an Anti-Parkinsonian Factor , 2001, Neuron.

[33]  J Q Trojanowski,et al.  A Hydrophobic Stretch of 12 Amino Acid Residues in the Middle of α-Synuclein Is Essential for Filament Assembly* , 2001, The Journal of Biological Chemistry.

[34]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[35]  J Q Trojanowski,et al.  Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  R. Samulski,et al.  Production of High-Titer Recombinant Adeno-Associated Virus Vectors in the Absence of Helper Adenovirus , 1998, Journal of Virology.

[37]  J. Trojanowski,et al.  Beta-synuclein modulates alpha-synuclein neurotoxicity by reducing alpha-synuclein protein expression. , 2006, Human molecular genetics.

[38]  J. Trojanowski,et al.  Beta-synuclein gene alterations in dementia with Lewy bodies. , 2004, Neurology.

[39]  E. Masliah,et al.  Beta-synuclein regulates Akt activity in neuronal cells. A possible mechanism for neuroprotection in Parkinson's disease. , 2004, The Journal of biological chemistry.

[40]  J. Trojanowski,et al.  Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. , 2002, Neuron.

[41]  E. Masliah,et al.  beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor. , 2001, Neuron.